PAPetr P. Arkhiri

Petr P. Arkhiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Petr P. Arkhiri has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Characteristics and Survival Rates in the Patients with Gastrointestinal Stromal Tumors: A Retrospective Single-Center Study

    by Natalia N. Mazurenko, Irina V. Tsyganova, Vladimir V. Yugay, Olga A. Anurova, Ilya S. Beliakov, Anna A. Lushnikova, Maxim P. Nikulin, Nikolay A. Kozlov, Petr P. Arhiri, Daria A. Filonenko, et al.

    Background/Objectives: Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal tumors that compose a heterogeneous group due to various molecular alterations. This study aimed to determine the molecular characteristics of patients with GIST treated between 2002 and 2017 and to follow their overall survival (OS) over 20 years. Methods: DNA was isolated from surgical biopsies of 490 patients with gut sarcomas and was analyzed using PCR and Sanger sequencing of hotspots of KIT, PDGFRA and BRAF genes. Immunohistochemical (IHC) staining was used to determine SDHB expression. Results: 417 GIST patients, including 13 children, were included; females predominated (male-to-female ratio 0.65), median age of 55.4 years old. KIT and PDGFRA mutations were found in 288 GISTs (69.1%) and 52 (12.5%), respectively. A total of 25 KIT and 3 novel PDGFRA mutations were revealed in 30 GISTs. KIT/PDGFRA mutations were not detected in 77 (18.5%) GISTs; among them were 2 NF1 GISTs, 10 with BRAF mutation, 14 with SDHB deficiency, and 3 “pediatric” GISTs. The overall survival (OS) of 280 GIST patients over more than 20 years. Genetic changes have a certain prognostic value in addition to such factors as tumor size, mitotic index, and location. The OS of GIST patients with KIT mutations was lower than that of patients with PDGFRA mutation, BRAF mutation, or SDHB deficiency, but the difference was non-significant. Conclusions: Our study highlights the heterogeneous nature and molecular features of GISTs in Russian population. The precise molecular characterization of the tumor should be considered an integral part of modern personalized GIST treatment.

  • Open Access

    Acinar cells of the pancreas as an independent predictor of the development of postoperative pancreatic fistula: A review

    by Danil V. Podluzhny, Alexey G. Kotelnikov, Igor V. Sagaydak, Alexander N. Polyakov, Nikolay E. Kudashkin, Peter P. Arkhiri, Bairamali I. Sakibov, Maryam R. Tamrazova, Omar A. Egenov, Поляков Александр Николаевич, et al.

    Analysis of data published in the modern literature on the role of the number of functioning acinar cells of the pancreas as a prognostic marker of the development of pancreatic fistula. The search for sources was carried out in the systems Clinicaltrials.gov, PubMed, Medline, NCCN, Scopus, Elibrary. In writing the literature review, 52 sources published from 2004 to 2022 were used. Included are studies reflecting the importance of functioning acinar cells at the edge of pancreatic resection, as well as other factors associated with the development of pancreatic fistula and other post-resection complications. A large number of acinar cells (40%) and a low collagen content (15%) in the edge of pancreatic resection significantly correlates with the development of pancreatic fistula. The content of adipose tissue in the edge of pancreatic resection showed no connection with the development of pancreatic fistula and other complications after surgery. Palpatory assessment of the structure of the pancreatic parenchyma is subjective and can lead to erroneous interpretation and adoption of inadequate tactics of preventive measures. Intraoperative counting of acinuses at the edge of pancreatic resection is easy to use, while not yielding to more complex methods for assessing the risk of post-resection complications and can be recommended as a routine method for predicting the occurrence of pancreatic fistula


  • Open Access

    Prognostic groups in retroperitoneal well-differentiated and dedifferentiated liposarcomas

    by А. Yu. Volkov, S. N. Nered, N. А. Kozlov, I. S. Stilidi, Р. Р. Arkhiri, Е. Yu. Antonova, S. А. Privezentsev, П. П. Архири

    Introduction. Liposarcoma is the most common retroperitoneal sarcoma. The majority of retroperitoneal liposarcomas are represented by highly differentiated and dedifferentiated liposarcomas. To date, clinical practice has not developed an effective method of the stratification of patients with RLPS into prognostic groups to determine the tactics of patient management. Objective. To develop a method for stratification of patients with retroperitoneal well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcomas into prognostic groups. Materials and methods. A retrospective study included 111 patients with WDLPS and 74 patients with DDLPS. The staging of the disease was carried out according to the modified TNM-classification, the analysis of survival was performed depending on the histological type of retroperitoneal liposarcoma (RLPS), the effect of age on overall survival (OS) was evaluated in WDLPS and DDLPS. Further, multivariate Cox regression analyzes were performed to assess the independent factors influencing the prognosis of patients. Then, we developed a methodology for stratification of patients into prognostic groups. OS and recurrence-free survival (RFS) were analyzed in accordance with it.Results and discussion. OS and RFS were statistically significantly worse in DDLPD compared with WDLPS (p = 0.000; log-rank test). At the same time, the results of the work demonstrated the absence of a statistically significant difference in OS and RFS depending on the degree of malignancy of DDLPS. In case of WDLPS and DDLPS, significant differences in OS were achieved only between groups of patients whose age was (at the time of the initial detection of RLPS) under 60 years and older (p = 0.008; p = 0.026; logrank test). Thus, the borderline value of the age of patients, which affects the prognosis, was determined – 60 years. OS and RFS were statistically significantly different between all prognostic groups (p = 0.000; log-rank test). The highest OS was achieved in the group with a “favorable prognosis”, while the shortest OS was in the group with the extremely poor prognosis (p = 0.000; log-rank test). The median OS in the “favorable prognosis” group was 225 (95% CI, 174, 276) months; in the “intermediate prognosis” group – 130 (95% CI, 115, 145) months; in the “poor prognosis” group – 90 (95% CI, 79, 101) months; in the “extremely poor prognosis” group – 22 (95% CI, 15, 29) months. The highest RFS was achieved in the group with a “favorable prognosis”, while the shortest RFS was achieved in the group with an “extremely poor prognosis” (p = 0.000; log-rank test). The median RFS in the “favorable prognosis” group was 80 (95% CI, 65, 95) months; in the “intermediate prognosis” group – 47 (95% CI, 33, 61) months; in the “poor prognosis” group – 26 (95% CI, 24, 28) months; in the “extremely poor prognosis” group – 10 (95% CI, 6, 14) months.Conclusion. The proposed method for stratification of patients with RLPS into prognostic groups demonstrates an adequate distribution of patients and the reliability of intergroup differences in the survival rate.


  • Open Access

    SDH-deficient gastrointestinal stromal tumors: paradoxical effect of imatinib

    by Daria A. Filonenko, Andrey A. Meshcheryakov, Petr P. Arkhiri, Maxim P. Nikulin, Evgeniia S. Kolobanova, Мещеряков Андрей Альбертович

    Succinate dehydrogenase deficient gastrointestinal stromal tumors (dSDH GIST) is a unique group of GISTs with an energy metabolism defect as the key oncogenic mechanism without mutations in the proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor a (PDGFRA). SDH-deficiency is a result of mutations in SDHA, SDHB, SDHC, SDHD. There are three variants of dSDH GIST: sporadic dSDH GIST, Carney triad or Carney-Stratakis syndrome. dSDH GISTs are characterized by young age, female prevalence, gastric location, multiple tumors, lymph node metastases, indolent behavior and poorly response to imatinib. Despite the literature data, we report the response to imatinib in patient with dSDH GIST. 21 year old female patient presented with incomplete Carney triad (multiply gastric GIST with liver and peritoneal metastases, left lung chondroma). The patient received imatinib with clinical response in a month and radiological response in three months-cystic transformation of primary gastric tumor and liver metastases. The duration of response was 8 months.

  • Open Access

    Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data

    by Maxim Sorokin, Roman Kholodenko, Maria Suntsova, Galina Malakhova, Andrew Garazha, Irina Kholodenko, Elena Poddubskaya, Dmitriy Lantsov, Ivan Stilidi, Petr Arhiri, et al.

    Sequential courses of anticancer target therapy lead to selection of drug-resistant cells, which results in continuous decrease of clinical response. Here we present a new approach for predicting effective combinations of target drugs, which act in a synergistic manner. Synergistic combinations of drugs may prevent or postpone acquired resistance, thus increasing treatment efficiency. We cultured human ovarian carcinoma SKOV-3 and neuroblastoma NGP-127 cancer cell lines in the presence of Tyrosine Kinase Inhibitors (Pazopanib, Sorafenib, and Sunitinib) and Rapalogues (Temsirolimus and Everolimus) for four months and obtained cell lines demonstrating increased drug resistance. We investigated gene expression profiles of intact and resistant cells by microarrays and analyzed alterations in 378 cancer-related signaling pathways using the bioinformatical platform Oncobox. This revealed numerous pathways linked with development of drug resistant phenotypes. Our approach is based on targeting proteins involved in as many as possible signaling pathways upregulated in resistant cells. We tested 13 combinations of drugs and/or selective inhibitors predicted by Oncobox and 10 random combinations. Synergy scores for Oncobox predictions were significantly higher than for randomly selected drug combinations. Thus, the proposed approach significantly outperforms random selection of drugs and can be adopted to enhance discovery of new synergistic combinations of anticancer target drugs.


  • Open Access

    Efficacy of surgical treatment of patients with localized gastrointestinal stromal tumors

    by Petr P. Arkhiri, I. S Stilidi, I. V Poddubnaya, S. N Nered, M. P Nikulin, V. Yu Bokhyan, O. B Abu-Khaydar, I. N Peregorodiev, S. A Melikov, N. Ts Tsymzhitova, et al.

    The main method of the treatment of patients with localized and locally advanced gastrointestinal stromal tumors (GIST) currently remains to be surgical, but its effectiveness is limited and determined by the degree of local expansion of the disease and radicality of the surgery. Before the era of the use of tyrosine kinase inhibitors (TKI) in the treatment of GIST patients the overall 5-year survival after radical surgery in the group of patients with size of the tumor larger than 10 cm failed to exceed 20%. For the time present with the comprehensive approach to the treatment indices of survival in these patients have significantly improved. Overall 5-year survival in patients with a high risk of disease progression reaches 93%. The most important prognostic factors in patients with primary localized GIST are: the size of the primary tumor, mitotic index, tumor location, mutation status and the morphological variant of the cellular structure of GIST.